<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699240</url>
  </required_header>
  <id_info>
    <org_study_id>pkuszh-2020-02</org_study_id>
    <nct_id>NCT04699240</nct_id>
  </id_info>
  <brief_title>Study of Lactobacillus in Adjuvant Treatment of RVVC</brief_title>
  <official_title>A Prospective, Case-controlled Randomized Study of Human Reproductive Tract Active Lactobacillus in Adjuvant Treatment of Recurrent Vulvovaginal Candidiasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Shenzhen Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are trying to determine if Clotrimazole vaginal tablets with oral Lactobacillus is better&#xD;
      than Clotrimazole vaginal tablets in Preventing the Recurrence of vulvovaginalcandidiasis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      vulvovaginal candidiasis is common disease in women. Its refractory and high recurrence rate&#xD;
      has always been a clinical problem. Some cases even recur several times a year, and those who&#xD;
      recur more than four times a year are diagnosed as recurrent vaginal candidal infection&#xD;
      Candidiasis, RVVC）。 The common clinical regimen for VVC is to strengthen and consolidate&#xD;
      clotrimazole vaginal tablets for up to 25 weeks. However, long-term antibiotic treatment will&#xD;
      lead to the decrease of vaginal microflora and the disappearance of inflammation and&#xD;
      pathogenic bacteria, which will greatly increase the probability of repeated infection and&#xD;
      become a barrier to clinical treatment. If probiotics are added in the treatment, the&#xD;
      abundance of lactobacillus can be ensured while antibiotic treatment is carried out, the&#xD;
      homeostasis of reproductive tract flora can be reestablished, the defense mechanism can be&#xD;
      improved fundamentally, and the re invasion of pathogenic bacteria can be reduced, which will&#xD;
      become a new treatment idea and method for radical cure of refractory RVVC.&#xD;
&#xD;
      We hypothesize that Clotrimazole vaginal tablets with oral Lactobacillus is better than&#xD;
      Clotrimazole vaginal tablets in Preventing the Recurrence of vulvovaginalcandidiasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The cure rate of RVVC,</measure>
    <time_frame>6 months</time_frame>
    <description>The cure rate of RVVC,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of RVVC</measure>
    <time_frame>6 months</time_frame>
    <description>Recurrence of RVVC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Recurrent Vulvovaginal Candidiasis</condition>
  <arm_group>
    <arm_group_label>Clotrimazole vaginal tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clotrimazole vaginal tablets+ Lactobacillus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times + Lactobacillus Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clotrimazole vaginal tablets</intervention_name>
    <description>Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months</description>
    <arm_group_label>Clotrimazole vaginal tablets</arm_group_label>
    <other_name>clotrimazole vaginal tablets（Bayer）</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole vaginal tablets+ Lactobacillus</intervention_name>
    <description>Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months Human Reproductive Tract Active Lactobacillus,4g,qd ,3months</description>
    <arm_group_label>Clotrimazole vaginal tablets+ Lactobacillus</arm_group_label>
    <other_name>Clotrimazole vaginal tablets+ Lactobacillus（Umeta-mimi）</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women be at least 18 years of age&#xD;
&#xD;
          -  Have symptoms of vulva irritation and or abnormal discharge&#xD;
&#xD;
          -  Meet the clinical criteria for RVVC&#xD;
&#xD;
          -  Willing to participate in research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Taking / injecting antibiotics in the past two weeks;&#xD;
&#xD;
          2. A woman who intends to be pregnant, pregnant or lactating;&#xD;
&#xD;
          3. Long term use of contraceptives and immunosuppressants;&#xD;
&#xD;
          4. Postmenopausal;&#xD;
&#xD;
          5. There was no same fixed sexual partner (RSP) before and after treatment&#xD;
&#xD;
          6. Patients with severe gastrointestinal diseases, including colorectal cancer, IBS, IBD,&#xD;
             chronic or acute diarrhea, long-term constipation, etc., or receiving gastrointestinal&#xD;
             surgery and abdominal surgery within one year, such as cholecystectomy;&#xD;
&#xD;
          7. Patients with severe heart, liver and kidney dysfunction, mental diseases, infectious&#xD;
             diseases, tumors, severe anemia, and severe autoimmune diseases (such as rheumatoid&#xD;
             arthritis, lupus erythematosus, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shangrong Fan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Shenzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yiheng liang, M.D.</last_name>
    <phone>86-755-83923333</phone>
    <phone_ext>5518</phone_ext>
    <email>liangyiheng.cn@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping liu, M.D.</last_name>
    <phone>86-755-83923333</phone>
    <phone_ext>5505</phone_ext>
    <email>253783006@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept Obstetrics and Gynecology</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiheng liang, M.D.</last_name>
      <phone>86-755-83923333</phone>
      <phone_ext>5518</phone_ext>
      <email>liangyiheng.cn@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Piu liu, M.D.</last_name>
      <phone>86-755-83923333</phone>
      <phone_ext>5505</phone_ext>
      <email>253783006@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Shenzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shangrong Fan</investigator_full_name>
    <investigator_title>Profesor</investigator_title>
  </responsible_party>
  <keyword>Recurrent Vulvovaginal Candidiasis</keyword>
  <keyword>Lactobacillus</keyword>
  <keyword>reproductive tract flora</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

